x

Posted 02 November, 2023

IMPEL PHARMACEUTICALS INC appointed Leonard S. Paolillo as new CEO

Nasdaq:IMPL appointed new Chief Executive Officer Leonard S. Paolillo in a 8-K filed on 02 November, 2023.


  The Board of Directors of the Company intends to appoint Leonard S. Paolillo as Interim President and Chief Executive Officer effective upon Mr. Adams's resignation.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of IMPEL PHARMACEUTICALS INC
Health Care/Life Sciences • Pharmaceuticals
Impel Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It engages in the development and commercialization of transformative therapies for patients suffering from diseases with high unmet medical needs with an initial focus on diseases of the central nervous system. The company was founded by Rodney J. Y. Ho, John D. Hoekman, and Michael P. Hite in 2008 and is headquartered in Seattle, WA.
Market Cap
$182K
View Company Details
Relevant filing section
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. 


On October 29, 2023, Adrian Adams gave notice of his resignation from his position as Chairman of the Board and as President and Chief Executive Officer of Impel Pharmaceuticals Inc. (the "Company") effective November 4, 2023. Mr. Adams' resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. 

The Board of Directors of the Company intends to appoint Leonard S. Paolillo as Interim President and Chief Executive Officer effective upon Mr. Adams's resignation. Mr. Paolillo's biographical information is included below: 

Mr. Paolillo has served as Chief Commercial Officer for the Company since March 2021. Prior to that, Mr. Paolillo served from August 2019 to February 2021 as Executive Vice President and Chief Commercial Officer of Kyowa Kirin Inc., the North American affiliate of Kyowa Kirin Co. Ltd., a global specialty pharmaceutical company based in Tokyo, as well as in other roles from March 2014 to July 2019. Prior, from May 2011 to January 2014 he served as senior director of sales at Warner Chilcott Pharmaceuticals where he led the women's healthcare, osteoporosis and urology sales forces. Mr. Paolillo began his healthcare career at EURO RSCG LIFE LM&P, a full-service healthcare advertising agency, before joining Warner Chilcott in March 2003, and holds a B.S. in business administration from Manhattan College. 


2